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Abstract 
Objectives: Demonstrate the safety and effectiveness of highly purified CD133+ autologous stem cells in critical 
limb ischemia (CLI).
Design: Prospective single-center not randomized. Clinicaltrials.gov identifier: NCT01595776
Methods: Eight patients with a history of stable CLI were enrolled in a period of 2 years. After bone marrow stimu-
lation and single leukapheresis collection, CD133+ immunomagnetic cell selection was performed. CD133+ cells 
in buffer phosphate suspension was administered intramuscularly. Muscular and arterial contrast enhanced ultra 
sound (CEUS), lesion evolution and pain management were assessed preoperatively and 3, 6 and 12 months after the 
implant.
Results: No patient had early or late complications related to the procedure. Two patients (25 %) didn’t get any relief 
from the treatment and underwent major amputation. Six patients (75 %) had a complete healing of the wounds, rest 
pain cessation and walking recovery. An increase in CEUS values was shown in all eight patients at 6 months and in 
the six clinical healed patients at 12 months and had statistical relevance.
Conclusions: Highly purified autologous CD133+ cells can stimulate neo-angiogenesis, as based on clinical and 
CEUS data.
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Background
Symptomatic peripheral arterial disease (PAD) has a 
prevalence of 3 % in a population aged 40 years and above 
and of 6  % in patients over 60. Critical Limb Ischemia 
(CLI) is the worst and terminal clinical picture of PAD 
often preceding gangrene and amputation: typical symp-
toms are rest pain refractory to analgesics lasting more 
than 2  weeks and ischemic lesions (Fontaine classifica-
tion stage 3–4 and Rutherford classification stage 4–6). 
CLI diagnosis is confirmed instrumentally by calf arterial 
pressure <50  mmHg, Ankle/Brachial Index (ABI) <0.5 
and Transcutaneous PO2 (TcPO2) <30 mmHg. The Inter-
Society Consensus for the Management of Peripheral 
Arterial Disease (TASC II) [1] stresses the absolute indi-
cation to revascularization for these patients either by 
surgical or endovascular treatment. Nevertheless in some 
cases, mostly due to lack of distal run off, revasculariza-
tion is not feasible or shows very low success rates. For 
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the above mentioned reasons, the prognosis of these CLI 
patients is poor, with a major amputation rate of about 
50 % at 1 year.
Many non-interventional treatments have been 
proposed for these “no-options” patients: spinal cord 
stimulation, prostanoids and prostaglandins admin-
istration, hyperbaric oxygen therapy and so on. More 
recently some authors have focused the attention on 
the local administration of stem cells, and particu-
larly Endothelial Progenitor Cells (EPCs). EPCs local 
administration effectiveness in post-ischemic myocar-
dial damage has been demonstrated in animal models 
and in humans [2–5]. Many observations lead to argue 
that the EPCs play a basic role in re-endothelization 
and neo-vascularization processes: actually the EPCs 
number may be reduced in peripheral blood in cardio-
vascular diseases, diabetes and rheumatoid arthritis 
and under the action of exogenous (as smoke habit) 
or endogenous (as high C-reactive protein levels) fac-
tors. Otherwise EPCs number may be increased by 
factors as physical exercise, estrogens, erythropoietin, 
statins and several cytokines or secreting proangio-
genic factors like hepatic growth factor (HGF), insulin 
like growth factor (IGF-1) and the vascular endothelial 
growth factor (VEGF). These observations persuaded 
some authors to apply this cell therapy approach to 
CLI [6].
Our starting experience in the treatment of no options 
CLI with EPCs in three patients has been previously 
reported [7]. The bench marks of our study are the use of 
a selected EPCs population to investigate more precisely 
the cellular mechanisms, and to assess whether patients 
with PAD treated with EPCs show variation in muscle 
perfusion as displayed by contrast enhanced ultrasound 
(CEUS).
According to the current guidelines, reliable diagnos-
tic tools for the management of patients with PAD, are 
ankle-brachial index (ABI), duplex ultrasound, transcu-
taneous oxygen pressure (TcPO2), magnetic resonance 
(MR), contrast computer tomography (CT scan) and 
conventional angiography (CA). Among imaging modali-
ties under development, micro bubble—based CEUS is a 
real-time, high spatial-resolution imaging technique that 
can easily be applied. Its high sensitivity, which provides 
detection of extremely low concentrations of micro bub-
bles, combined with the true blood pool distribution of 
contrast agent, gives CEUS the potential to help visualize 
and quantify the vasculature in vivo. CEUS was recently 
proposed as a valuable method to detect perfusion defi-
cit and collateralization in patients with PAD [8, 9]. This 
method has been also validated for the detection of 
impaired microcirculation in patients with diabetes mel-
litus [10].
We present our experience in eight no-options CLI 
patients transplanted with peripheral immune-selected 
apheresis-derived autologous CD133+ cells and followed 
up with CEUS for 12 months.
Patients and methods
Type of the study
Prospective single centre not randomized.
Clinicaltrials.gov identifier: NCT01595776
Aim of the study
To assess the safety, feasibility and efficacy of local intra-
muscular administration of autologous immuno-selected 
CD133+ cells in patients suffering from CLI. The proto-
col started at our institution in July 2011 with the local 
Ethical Committee (EC) approval (number CHVAS-01-
08-10/03/08). The investigation conforms with the prin-
ciples outlined in the Declaration of Helsinki.
Enrolment criteria
All the patients enrolled were suffering from clinical sta-
ble CLI according to the TASC 2 definitions [1] and had 
no revascularization option, on the basis of contrast CT 
scan, RM or angiography imaging and the evaluation of 
our vascular and endovascular team. A detailed informed 
consent, approved by our EC, had been required.
Exclusion criteria
Patients under 18 and over 70  years of age. Elderly 
patients have been excluded because of expected bone 
marrow low responsiveness. Clinical unsteadiness of CLI 
(such as gangrene requiring major amputation) and poor 
life expectancy are exclusion criteria for supposed latency 
of the EPCs action. Severe systemic illness was judged to 
increase the risk of bone marrow stimulation. Complete 
inclusion and exclusion criteria are depicted in Table 1.
Patients
Between September 2011 and September 2013 we 
enrolled eight patients with a history of Rutherford 
stage 4 (rest pain) or 5 (small ischemic lesions) PAD. 
All patients had previous vascular imaging (contrast 
CT or MR or angiography) excluding revascularization 
options, either endovascular and surgical and encoun-
tered inclusion criteria. Every patient underwent routine 
physical and instrumental examination including electro-
cardiogram, chest X-ray and blood sample analysis. The 
patients’ features are summarized in Table 2. The median 
age was 46.8 (SD 11.8, range 37–69  years), with a M:F 
ratio of 3:1. Younger patients met Buerger disease crite-
ria (n = 4, 50 %), whereas others had pure atherosclerotic 
lesions. Only one patient (ID 7, female) had diabetes mel-
litus. Six patients out of eight had ischemic lesions on 
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the forefoot (Rutherford stage 5) with poor healing and a 
long history of wound treatment. All patients complained 
moderate/severe pain and took high doses of analgesics 
(slow release opiates in two cases).
CEUS imaging protocol
Two operators who were blinded to treatment performed 
CEUS for all patients. The imaging criteria were: (1) 
reduced transmit power, at approximately 7–10 frames 
per second and one focus well below the level of the 
target to ensure a more uniform pressure field. (2) dual-
mode presentation of a grayscale image side-by-side with 
the contrast image facilitating real-time identification of 
anatomic structures and region of interest (ROI) selec-
tion. (3) Image loops of approximately 60 s. (4) Uniform 
gain across the image and avoid gain saturation. (5) The 
time gain compensation (TGC) set such that before con-
trast arrival a uniform black image was shown.
A vial of contrast agent (SonoVue BR1; Bracco, Milan, 
Italy) was prepared at a concentration of about 2 ×  108 
sulfur hexafluoride—filled micro bubbles per milliliter, 
according to the manufacturer’s recommendations. The 
position of the probe was recorded for each patient in 
order to maintain the same position during follow up. 
The injection was made with the patient supine and after 
10  min of rest to avoid exercise related micro-vascular 
dilatation. The radiologist maintained a constant image 
plane with the aid of the tissue (fundamental image) of 
the “Contrast Side/Side” imaging mode.
Image analysis
The main image analysis tasks were: (1) identification 
of anterior tibialis artery (ATA) area, (2) selection of a 
representative region of normal anterior tibialis mus-
cle (ATM) and (3) formulation of time-intensity curves 
(TIC). Two manually defined ROI, 2 and 4  cm sided-
squares, were placed, respectively, over the ATM with no 
evidence of arterial branches, over ATA and over a small 
tibialis arterial branch. The ROIs were placed in the same 
anatomical position for each patient to avoid unwanted 
differences during follow up examinations. One TIC was 
obtained for each ROI. The image loops were transferred 
to a personal computer for further analysis. From the 
analysis of TIC, we computed regional blood flow (RBF) 
and regional blood volume (RBV). TIC were extracted 
using commercial quantification software (QontraXt 
v.3.60, AMID, Rome, Italy). This software allows manual 
ROI selection, measurement of the selected ROI area and 
provides linear data for the TIC. For the ROI in the nor-
mal ATM, effort was made to place the region in an area 
without large vessels. The ATA ROI was a 2  cm square 
area and the ATM ROI was a 4  cm square area. TICs 
were obtained by computing the mean intensity of pixels 
comprised within the ROI at each time point. For each 
image loop were calculated:
Table 1 Inclusion and exclusion criteria
Inclusion criteria
 Age between 18 and 70 years
 CLI (TASC 2)
 None surgical nor endovascular option
 Written informed consent
Exclusion criteria
 Clinical instability
 Extensive gangrene (proximal to forefoot)
 All serious systemic disease
 Life expectancy <24 months
 Child bearing age
 Allergy
 Previous similar studies
 Previous experimental drug studies within 3 months
 Conflict of interest with the study
Table 2 Patients baseline
AH arterial hypertension, HC hypercholesterolemia, ESH ex smoke habit, PAD peripheral arterial disease, BD buerger disease, AS active smoker, DM diabetes mellitus
Pain scale: +mild, ++ moderate, +++ severe
ID Sex Age Risk factors Diagnosis Lesion’ site and extension Rest pain
1 m 57 AH, hyperuricemia, HC, ESH PAD Left leg ulcer, 16 cm +++
2 m 39 ESH BD Left foot ulcer, 2 cm ++
3 m 37 Hyperhomocysteinemia, ESH BD Left forefoot amputation dehiscence, 15 cm +++
4 m 69 AH, ESH, HC PAD Right foot ulcer, 5 cm ++
5 f 41 ESH BD Right foot ulcer, 1 cm ++
6 m 34 ESH BD Left finger amputation dehiscence, 10 cm +++
7 f 52 AS, AH, DM PAD None +++
8 m 49 ESH PAD None ++
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  • RBV which consists in the total amount of contrast 
media within the selected ROI, in a period of time. 
Due to the characteristics of US contrast media, it 
reflects the quantity of blood in a defined region. It 
is directly related to the area under the curve (AUC).
  • RBF consists in the contrast media flow (related to 
the blood flow) in a selected ROI. It is related to the 
mean transit time.
Bone marrow stimulation
Human recombinant granulocyte colony-stimulating 
factor (rhGCSF) was administered subcutaneously 
for 4–5 consecutive days at a dosage of 10 µg/kg daily, 
split in two doses. Starting from the third day of stem 
cells mobilization, the CD34+/133+ cells count was 
monitored daily by cytofluorimetric analysis. The 
minimum CD34+/133+ cells count acceptable for 
leukapheresis collection was 20 and 10/µl, respec-
tively. Patients were monitored for any G-CSF related 
side effects.
Leukapheresis (LKF) collection
A single LKF collection was planned for each patient 
using a third generation cell separator device (Spec-
tra Cobe, Lakewood, CO, USA), processing at least 2.5 
blood volumes according to our internal protocol for 
stem cell collection. Immediately after the LKF collec-
tion, a sample from patient’s peripheral blood was taken 
for haemocytometric analysis to evaluate platelet count 
and haemoglobin levels. Each LKF collection was diluted 
with 10 % acid citrate dextrose (ACD-A) and maintained 
overnight at 4  °C degrees before immuno-magnetic cell 
selection.
Immunomagnetic cell selection
CD133+ immunomagnetic cell selection (ICS) was 
performed the day after LKF collection using the Clini-
MACS (Miltenyi Biotec) device according to the manu-
facturer’s standard protocol.
Quality controls
A sample taken from the CD133 cell positive fraction 
was seeded for short term (14  days) clonogenic assays 
to evaluate the quality of immunoselected stem cells in 
terms of proliferative capacity. A standard mixture of 
methylcellulose plus recombinant human growth factors 
was employed (Stem Cell Technologies, Vancouver, BC, 
Canada; MACS Media, Miltenyi Biotec GmbH, Bergisch 
Gladbach,Germany). Microbial cultures on the waste 
bag containing the negative fraction were carried out to 
detect aerobic-anaerobic bacteria and fungal contami-
nation. A sample of 10 ml was inoculated in the culture 
medium (Bact/Alert FA and BacT/Alert FN, Organon 
Teknika Corp., Durham, NC) and incubated for 10 days 
at 37 °C.
Cytofluorimetric analysis
Samples obtained from peripheral blood before mobiliza-
tion with G-CSF, at time of LKF and after immunomag-
netic cell selection were analyzed by flow cytometry to 
evaluate the expression of specific stem cell and endothe-
lial antigens. Becton–Dickinson FACSCanto was 
employed for all flow cytometric analysis with a lyse no-
wash technique, using the following monoclonal anti-
bodies: anti-CD45 fluorescein isothiocyanate (FITC) 
(Becton–Dickinson, San Jose, CA, USA), anti-CD34 Peri-
dinin-chlorophyll-protein complex (PerCP) (8G12 clone, 
Becton–Dickinson), anti-CD133 phycoerythrin (PE) 
(AC133 clone, Miltenyi Biotec) and anti-VEGF-R2 allo-
phycocyanin (APC) (R&D systems), following the manu-
facturer instructions.
Each sample was acquired with BD FACSCanto record-
ing 100.000 events inside the lymphocyte plus monocyte 
gate. Data files were analyzed with FACS Diva 6.1 soft-
ware. Viability was assessed using 7-amino-actinomycin 
D (7-AAD) (Molecular Probes, Eugene, OR, USA).
Implant procedure
After loco-regional anesthesia and below the knee cuta-
neous disinfection, 45–48  ml of autologous CD133+ 
cell in buffer phosphate (Miltenyi Biotec) suspension 
was administered intramuscularly with 1 ml deep injec-
tions through a 18G needle. The injections were so allo-
cated: 10  ml in the anterior compartment of leg, 10  ml 
in the superficial posterior compartment, 10  ml in the 
deep posterior compartment, 10  ml in the lateral com-
partment and the remaining part in the foot (Additional 
file 1: Figure S1).
Baseline assessment and follow up
Pain assessment was carried out with a personal scale of 
3 degrees (mild, moderate and severe) and the pain kill-
ing drugs use monitored. Ischemic lesions were treated 
weekly by a wound management skilled nurse. CEUS, 
lesion evolution and pain management were assessed at 
baseline and 3, 6 and 12 months after the implant.
Statistical analysis
All quantitative variables were normally distributed (Sha-
piro–Wilk test) and so the results were expressed as mean 
values and standard deviation (SD); qualitative variables 
were summarized as counts and percentages. Pearson’s r 
coefficient was used to test correlation between two study 
variables. Linear regression models for repeated measure 
were used to assess the increase over time of the CEUS 
parameters. Data analysis was performed with STATA 
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statistical package (release 11.1, 2010, Stata Corporation, 
College Station, TX, USA).
Results
Patient’s mobilization and LKF
No relevant side effects related to G-CSF administration 
were registered. A single LKF collection per patient was 
performed. No side effects were registered. Patients did 
not require any red blood cells or platelet transfusion 
after LKF procedures. Total nucleated cells (TNC) con-
tent and viability in peripheral blood of the eight patients 
enrolled are depicted in Table 3.
Immunomagnetic cell selection
The immunomagnetic cell selection was carried out the 
day after LKF collection. Almost all cells expressing CD133 
antigen also expressed CD34 antigen. The mean CD133+ 
cell recovery was 46.1  % (SD 21.5, range 9.9–81.7). The 
mean purity was 85.4 % (SD 19.6, range, 37.2–96.5). TNC 
viability was always >90  %. Results of cytofluorimetric 
analysis performed on samples obtained from the posi-
tive fraction are detailed in Table 3. The mean number of 
CD133+ infused cell per limb kilogram was 25.2 × 106 (SD 
13.8; range 2.6–42.2). Clonogenic assays demonstrated the 
maintained proliferative capacity of immunoselected stem 
cells. The result of microbial cultures was always negative.
Clinical results
No patient had early or late complications related to the 
procedure. Two patients (number 3 and 7, 25  %) didn’t 
get any relief from the treatment and underwent major 
amputation. Patient number 3 had lesion and pain wors-
ening and was amputated below the knee after 5 months. 
Patient number 7 had pain worsening and final gan-
grene of the foot and underwent above the knee ampu-
tation after 7  months; this patient had diabetes and a 
heavy smoking habit (40 cigarettes/day) persisting in 
spite of physician’s indication. Five patients (number 
1, 2, 4, 5 and 6, 62.5  %) had a complete healing of the 
wounds, complete rest pain cessation and walking recov-
ery or increased pain free walking distance. One patient 
(number 8, 12.5  %) had rest pain cessation, and a mild 
improvement in pain free walking distance. None statis-
tical correlation has been found between the number of 
infused CD133+ cells and the clinical results.
CEUS
An increase in RBF and RBV was shown in all eight patients 
at 3 and 6 months and in the six clinical healed patients at 
12 months and has statistical relevance: at 12 months mean 
increasing for TAM-RBV was 48.8 % (p = 0.018), for TAM-
RBF 59.4 % (p = 0.0016), for ATA-RBV 52.8 % (p = 0.017) 
and for ATA-RBF 48.6 (p = 0.007). The trends in increas-
ing values at 3, 6 and 12 months for RBV and RBF, both in 
artery and in muscle, are depicted in Fig. 1. No statistical 
correlation between RBF and RBV value, and CD133+/
CD34+ infused cells was found at 6 and at 12  months. 
Additional file 2: Figure S2 shows the correlation between 
clinical healing and CEUS values improvement in patient 1. 
Table 4 shows a synopsis of the results. 
Discussion
CLI is a manifestation of PAD that includes patients 
with typical chronic ischemic pain at rest or patients 
with ischemic skin lesions, either ulcers or gangrene. 
The term CLI should only be used in relation to patients 
with chronic ischemic disease, defined as symptoms last-
ing more than 2 weeks. The diagnosis of CLI should be 
confirmed by ABI, toe systolic pressure or transcutane-
ous oxygen tension. Ischemic rest pain most commonly 
occurs below an ankle pressure of 50  mmHg or a toe 
pressure less than 30 mmHg [1].
Table 3 Cytofluorimetric analysis
PB peripheral blood, LKF leukapheresis, IS immunoselection, WBC white blood cells, MV mean values












CD34+ (106) CD133+/ 
CD34+ (106)
CD133+ (106)
1 48.6 51.0 34.5 311.4 232.3 140.6 60.5 92.5 30.0
2 47.2 95.9 56.6 486.0 484.7 233.1 48.1 89.2 41.1
3 52.9 105.7 105.5 737.9 706.3 361.1 51.1 93.9 42.2
4 39.1 35.2 25.1 401.0 282.6 100.3 35.5 92.9 16.4
5 51.6 63.1 50.7 333.0 205.4 20.4 9.9 37.2 2.6
6 77.0 55.4 42.2 369.2 317.6 94.0 29.6 90.0 16.1
7 41.7 47.7 7.0 223.0 154.9 126.5 81.7 96.5 20.1
8 26.6 58.5 44.1 603.5 455.2 238.9 52.5 91.1 33.2
MV 48.1 54.7 45.7 433.1 354.9 164.4 46.1 85.4 25.2
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The first large report on the use of bone marrow-
derived mononuclear cells (BM-MNC) in limb ischemia 
was the therapeutic angiogenesis by cell transplanta-
tion (TACT) study by Tateishi-Yuyama et al. At 4 weeks, 
ankle-brachial index (ABI) was significantly improved in 
legs injected with BM-MNC and similar improvements 
were seen for transcutaneous oxygen pressure. They 
concluded that autologous implantation of BM-MNC 
could be safe and effective for achievement of therapeu-
tic angiogenesis, because of the natural ability of marrow 
cells to supply endothelial progenitor cells and to secrete 
various angiogenic factors or cytokines [11]. Since then, 
several trials were published, both using BM-MNC, and 
mobilized peripheral blood mononuclear cells (PBMNC) 
with intra-arterial or intra muscular administration, well 
reviewed by Lawall et al. [12].
In their review, Lawall et  al. sustain that the role of 
“EPCs” in human angiogenesis in the setting of periph-
eral vascular obstruction remains doubtful, and the 
translation of a truly “EPC” based endothelial repair 
into clinic practice has not been achieved so far. The 
well substantiated concept of arteriogenesis strength-
ens the importance of several different bone marrow cell 
types, however all sharing a monocytic phenotype. They 
migrate to the perivascular space of sprouting collater-
als and induce collateral artery growth by the release of 
angiogenic growth factors. A growing body of evidence 
strongly suggests that these secreted molecules mediate 
a number of protective mechanisms including cell sur-
vival, neo-vascularization, remodeling, and proliferation. 
The regulatory system governing paracrine factor release 
appears to be complex and dependent on spatiotemporal 
parameters. [13].
Based on available data, cell therapies in PAD based on 
the application of whole BM-MNC or on whole stimu-
lated PBMNCs are more successful than methods which 
use subfractionated cell preparations [12], e.g. CD 133+ 
[14] or highly purified CD 34+ cells from peripheral 
Fig. 1 The diagrams show the percentage increase of both RBV and RBF both in muscle and in anterior tibial artery. RBF regional blood flow, RBV 
regional blood volume. In the x axis are months of follow-up. In the y-axis is the percentage of increase of the values of RBV and RBF compared to 
the baseline. Dotted lines represent single patient values. Continue line represents the mean percentage increase with the statistical significance. P 
values compare the value of mean increase to the baseline
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blood after granulocyte- colony stimulating factor 
(G-CSF) mobilisation only [15]. Nevertheless available 
data are very scarce about efficacy of a specific subset 
cells population versus the entire pool of mononuclear 
cells, because great majority of the previous and ongo-
ing studies employ BM-MNC or PBMNCs, due to both 
lower costs and relative simplicity of the method. Except 
the case report of Canizo et al., the only previous study 
employing autologous selected CD 133+ cells is by Burt 
et al.: they treated nine patients with positive results in 7 
[16].
Previous EPCs in CLI studies considered only data 
measured with ABI and TcPO2. As a matter of fact both 
ABI and TCpO2 have an intra and inter patient variability 
due to detection method, operator experience, vasodila-
tation state and emotional stress, that make standardiza-
tion difficult. Moreover, in case of very low velocity flow, 
as in peripheral blood circulation in CLI, ABI detection 
variability increases [17]. CEUS offers a reliable method 
to measure peripheral blood flow, and is a valid alter-
native: it’s equally a non-invasive method, because the 
medium contrast hasn’t got any contraindication, except 
hypersensitivity, and the assessment method is not oper-
ator, but dedicated software related. It has only a mini-
mal intra patient variability, when the detection method 
is accurate.
The aims of our study are (1) to demonstrate that a 
highly purified autologous stem cells population can 
induce neo-angiogenesis in a safe, feasible and effective 
way and (2) to assess neo-angiogenesis with a non-inva-
sive method as most objective and reproducible as pos-
sible. In consideration of the end stage disease character 
of CLI, we didn’t considered ethical randomizing eligible 
patients. The possible advantages in studying a specific 
cells population in order to understand the mechanisms 
of neo-angiogenesis are to avoid the overlapping effects 
of entire MNC populations infused and as second step 
to better identify the cytokines pattern, derived from 
a single cell type, given the hypothesis of a paracrine 
mechanism.
Stem cells mobilization with G-CSF administration 
induce a high white blood cells count (WBCc) and a 
subsequent theoretical blood hyper viscosity. In patients 
with CLI blood hyper viscosity can be an issue. In our 
series the mean WBC count at the 4th day after mobili-
zation was 48.1 ×  106/ml (range 26.6–77). These values 
are similar to these observed in healthy donors mobilized 
for allogeneic hematopoietic stem cell transplant. Even in 
the patient (ID = 7) with the highest WBCc (77.0 × 106/
ml) we didn’t observe any significant side effect related 
to blood hyper viscosity. However, we administered 
a prophylactic dose of low molecular weight heparin 
(3800/4000 UI/daily) considering the pro thrombotic risk 
related to G-CSF administration and patient immobiliza-
tion. Remarkably also the CD34+ and CD133+ mobili-
zation in these patients is comparable to healthy donors 
showing that their stem cell reservoir is not depleted. 
Stem cell collection was performed following our internal 
protocol, processing 2.5 blood volumes without any rele-
vant side effects. On the whole we can argue that patients 
with compromised peripheral circulation can tolerate 
very well both mobilization and LKF. The wide range of 
CD133+ cell recovery after the ICS may be related to the 
different antigen expression on the stem cell surface. All 
the immunoselected CD133+ cell samples showed an 
high in  vitro clonogenic potential (similarly to hemato-
logic field) demonstrating the good quality of the prod-
uct infused. Nevertheless the purity was always very high 
(≥90 %), except in one case (ID = 5), showing that every 
patient, but one, was treated with a single cell population. 
From this point of view, we obtained results comparable 
with the study of Burt et al. [16].
Altogether, 6 out of 8 patients (75  %) had clinical 
improvement, with ulcer healing, cessation of rest pain, 
increased walk pain free distance and above all, avoided 
amputation and maintained their improvement for a 
long period of time. Indeed they had the longest follow 
up so far in literature, 12 months with CEUS and at least 
18 months from a clinical point of view. The graphics in 
Fig. 1 show the increase (in percentage) from baseline of 
RBV and RBF, both for ATM and ATA: mean percentage 
increase (continuous line) is always positive and statis-
tically significant (see also Table  4 for p values). Clini-
cal improvement is consistent with instrumental data 
showing an increased blood flow in the limb, reason-
ably related to an induced neo-angiogenesis. Neverthe-
less other important local factors may be involved both 
in initiating and maintaining angiogenesis, like resident 
cells and chemokines and cytokines environment. Data 
demonstrate that the resident progenitor cells could dif-
ferentiate into a variety of cell types in response to dif-
ferent culture conditions. However, collective data were 
obtained mostly from in vitro culture assays and pheno-
typic marker studies. There are many unanswered ques-
tions concerning the mechanism of cell differentiation 
and the functional role of these cells in vascular repair 
and the pathogenesis of vascular disease [18].
Patient 3, despite the maximum values of cell dose 
infused (42.2 × 106/limb kg) showed a complete lack of 
responsiveness both clinical, and instrumental (Table 4). 
Conversely, Patient 5 received the lowest dose of 
CD133+ cells with the lowest purity (Table 3): however 
she showed a satisfactory clinical response (ulcer healing, 
rest pain relief and increased pain free walk distance) and 
TAM-RBV/RBF increasing (+28.6 and +42.9, respec-
tively). We can speculate that these opposite results are 


























































































































































































































































































































































































































































































































































































































































































































Page 9 of 10Arici et al. J Transl Med  (2015) 13:342 
related not exclusively to the cell dose infused, but also 
to responsiveness of the resident stem cells. Indeed we 
didn’t find any statistical correlation between the number 
of infused CD133+ cells (106 per limb kg) and the clinical 
and CEUS results.
Patient 7 showed apparently conflicting results: at 
6  months TAM-RBV/RBF were increased around 77  % 
with a slightly improvement of clinical condition. Unfor-
tunately the following month she developed a sudden 
worsening in the limb ischemia, with subsequent above 
the knee amputation. It’s crucial to emphasize that the 
patient had insulin dependent diabetes mellitus (IDDM) 
and a heavy smoking habit (around 40 cigarettes daily). 
We can suppose a negative role of IDDM and a pre-
cipitating role of the smoke habit during the transient 
neo-angiogenesis process, as assessed by CEUS values 
increasing. However impaired angiogenesis in diabetes 
has been already demonstrated both in animal models 
and in humans [19, 20].
In conclusion, our study shows interesting perspective 
and issues. Highly purified autologous CD133+ cells, 
routinely employed in transplant for oncohematologic 
diseases, can stimulate neo-angiogenesis, either directly 
or through a paracrine effect, as based on clinical (ulcer 
healing, rest pain cessation, increasing pain free walk 
distance and limb salvage) and CEUS data. Our study 
gives an instrumental demonstration of neo-angiogene-
sis. The limits of the study are the lack of randomization, 
which we judged unethical for this kind of end-stage 
disease, and the low number of patients, mainly due to 
the restrictive inclusion and exclusion criteria. Goals for 
future studies are to enrol a major number of patients 
including also less advanced stages of PAD, and to con-
sider other powerful stem cell sources as cord blood 
derived or mesenchymal stem cells.
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